Dissertation/Thesis
RaRaMa - The Gap 'Cancer & Coherence'
| Τίτλος: | RaRaMa - The Gap 'Cancer & Coherence' |
|---|---|
| Συγγραφείς: | Hansley, Dustin |
| Στοιχεία εκδότη: | Zenodo |
| Έτος έκδοσης: | 2025 |
| Συλλογή: | Zenodo |
| Θεματικοί όροι: | cancer targeting, frequency medicine, quantum biophysics, Biomedical Engineering, Biomedical Engineering/classification, Biomedical Engineering/education, Biomedical Engineering/instrumentation, Biomedical Engineering/ethics, Biomedical Engineering/statistics & numerical data, Cancer, Cervical cancer, Liver cancer, Prostate cancer, Pancreatic cancer, Lung cancer, Skin cancer, Cancer risk, Breast cancer, Cancer Survivors, Cancer Pain/immunology, Cancer Pain/pathology, Cancer Pain/rehabilitation |
| Περιγραφή: | Comprehensive RaRaMa Frequency Cancer Targeting System with Mathematical Foundations and Validations We present a comprehensive theoretical framework for precision cancer targeting using the RaRaMa frequency equation f* = c_eff/(4d_molecular), integrating quantum mechanics, wave physics, and biological resonance phenomena. The mathematical foundation spans from the fundamental vibrational frequency equation ν = (1/2π)√(k/μ) through the Schrödinger equation for molecular vibrations to complex biological systems described by the Peyrard-Bishop Hamiltonian for DNA breathing modes and Elastic Network Models for protein dynamics. This framework transforms cancer treatment from generic chemotherapy to personalized dietary interventions targeting specific molecular frequencies across 90+ therapeutic food compounds and 53 distinct cancer types. Practical Implementation System: The framework categorizes therapeutic food compounds into four frequency ranges optimized for different biological targets: Ultra-High Frequency compounds (72.1-64.7 THz) including isothiocyanates, caffeine, and sulforaphane for precision DNA targeting; High Frequency compounds (63.2-52.1 THz) including quercetin, curcumin, and piperine for enzyme active sites; Medium Frequency compounds (46.5-29.6 THz) including berberine, EGCG, and lycopene for membrane proteins; and Low Frequency compounds (26.2-10.2 THz) including beta-glucan and pectin for large molecular complexes. Personalized Cancer Protocols: Complete treatment protocols were developed for 53 cancer types across 12 major categories including brain cancers (glioblastoma, astrocytoma), lung cancers (adenocarcinoma, squamous cell), breast cancers (HER2+, triple-negative), blood cancers (AML, CLL), and others. Each protocol specifies exact compound combinations, timing sequences, and bioavailability enhancement strategies tailored to cancer-specific molecular targets. Precision Frequency Matching: Perfect therapeutic matches within 5% tolerance include Berberine targeting KRAS G12 ... |
| Τύπος εγγράφου: | Thesis |
| Γλώσσα: | unknown |
| Relation: | https://zenodo.org/records/17118085; oai:zenodo.org:17118085; https://doi.org/10.5281/zenodo.17118085 |
| DOI: | 10.5281/zenodo.17118085 |
| Διαθεσιμότητα: | https://doi.org/10.5281/zenodo.17118085 https://zenodo.org/records/17118085 |
| Rights: | Creative Commons Attribution 4.0 International ; cc-by-4.0 ; https://creativecommons.org/licenses/by/4.0/legalcode |
| Αριθμός Καταχώρησης: | edsbas.1B401DA7 |
| Βάση Δεδομένων: | BASE |
καταχωρήστε σχόλιο πρώτοι!